To increase the robustness, here a 5-fold cross-validation was implemented
LlewellynDCLogan EllisHAylwinSJOtarijaEGreenSSheridanWet alThe efficacy of GLP-1RAs for the management of postprandial hypoglycemia following bariatric surgery: a systematic review
Drivers of cardiovascular benefit: Reduction in MACE-3 events occurred early, soon after treatment initiation, before any significant weight change was achieved
According to FDA labeling, nausea occurs in 44% of patients on Wegovy and 30% of patients on Zepbound, with vomiting, diarrhea, and constipation also frequently reported
The Hidden Problem: Most Patients Dont Know If Their Compounded Tirzepatide Is Still Good People assume tirzepatide is stable, predictable, and long-lasting